Morningstar Quantitative ratings for equities (denoted on this page by) are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies withratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating. Click here for more on how to use these ratings.
Biolidics Ltd is engaged in research, experimental development, marketing, and distribution of biotechnology, life and medical science and electronics related industrial design services and investment holding. Its segments include Cancer; Infectious diseases; Laboratory services; and Corporate segment. It derives major revenue from The infectious diseases segment that involves the identifying and assessing potential collaboration partners, technology, products and services, product development, innovation and improvement and the management of global distributorship network and direct customers in the infectious diseases field. Its operations are spread across Singapore, Japan, China, Europe, United States, Hong Kong, Philippines, Indonesia, and Others.
Singapore, 577177, Singapore